Materia, the mother company of Materia Malta, announced that it has commenced sales of the first medical cannabis flower produced at its EU GMP certified manufacturing site.
‘Carbasi Verde’, the company’s inaugural product, can now be purchased from pharmacies all over the islands and will be shipped out to Germany and the UK.
“The journey began in earnest over two years ago, so we’re elated to be offering patients Materia manufactured and branded medical cannabis,” Materia’s Europe Managing Director, Nick Pateras, said.
“Out Maltese site is truly state-of-the-art, and with our team’s deep pharmaceuticals expertise we’re confident that Materia Malta will become one of the most important production facilities in Europe’s cannabis supply chain,” he continued.
‘Carbasi Verde’ was released into the market with a potency of 21.7% THC, following successful completion of Materia Malta’s first production cycle.
“Materia has been at the forefront of Malta’s cannabis industry since we moved quickly to become a European leader in this field,” Malta Enterprise CEO Kurt Farrugia said, congratulating the company.
“We’re extremely proud to see locally produced medicinal products available to Maltese patients and are excited to continue supporting Materia’s talented team as the company expands its presence across the content,” he concluded.
Jamie Galea appointed Director of Account Management at Mastercard
Prior to this post, he worked in business development
David Valenzia appointed to Salvo Grima Group’s board of directors
David Valenzia has considerable experience in assisting with business development projects and corporate restructuring.
Nathan Farrugia completes 2,000km East Africa cycling challenge in aid of renal patients
From Mombasa, Kenya, to Kigali, Rwanda.
WATCH: Service charge must go to employees, not help cover costs, catering association President says
If a service charge is included, it should be written clearly on the menu, she says.
